Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Brain scans and imaging

Topic: Plasma and spinal-fluid biomarkers

INTRODUCTION: Central nervous system (CNS) pathologies have ocular manifestations due to direct and/or retrograde degeneration of the visual pathways, most often related to a direct injury to the optic nerve, retinal ganglion cells and/or its surrounding cells. These ocular manifestations can be recognized and monitored by a non-invasive technique called Optical Coherence Tomography (OCT). AREAS COVERED: This review article describes the OCT technique and its application in various neurological pathologies. OCT helps in the measurement of retinal nerve fiber layer thickness (RNFLT) and macular thickness which consists of retinal ganglion cells. OCT provides a near-histological level of image resolution up to 5µm by using principles of interferometry that can detect CNS inflammatory, as well as degenerative, pathologies (i.e Multiple Sclerosis, Parkinson's disease and Alzheimer's Disease etc.) at initial clinical and possibly subclinical stages. Expert Commentary: RNFLT and macular volumes measured by OCT can serve as biomarkers for early recognition and progression of a variety of neurological disease, although the specificity of these findings in clinical diagnosis requires further refinement. An early biomarker can help in an earlier therapeutic intervention and thus preventing further progression and provide the opportunity for possible regenerative interventions of the underlying disease process. With the advent of "next-generation" OCT technology an increase in use is foreseen in research as well as in clinical practice.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Gupta, S., Zivadinov, R., Ramanathan, M., & Weinstock-Guttman, B. (2016). Optical coherence tomography and neurodegeneration: are eyes the windows to the brain? Expert review of neurotherapeutics. https://doi.org/10.1080/14737175.2016.1180978

Vancouver

Gupta S, Zivadinov R, Ramanathan M, Weinstock-Guttman B. Optical coherence tomography and neurodegeneration: are eyes the windows to the brain? Expert review of neurotherapeutics. 2016. doi:10.1080/14737175.2016.1180978. PMID: 27138997.

BibTeX

@article{gupta2016-27138997,
  author  = {Gupta, Sahil and Zivadinov, Robert and Ramanathan, Murali and Weinstock-Guttman, Bianca},
  title   = {{Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?}},
  journal = {Expert review of neurotherapeutics},
  year    = {2016},
  doi     = {10.1080/14737175.2016.1180978},
  pmid    = {27138997},
  url     = {https://doi.org/10.1080/14737175.2016.1180978}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 38/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multi-centre collaboration left out, no data; Indexed in PubMed 2 of 2; Free to read left out, no data. 21 of the 56 points it could be judged on, which is 38 of 100. Total 38 of 100.21 of the 56 points we could judge = 38 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 21 of the 56 points we could judge it on, which is 38 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Expert review of neurotherapeutics)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2016 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multi-centre collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 27138997)
Free to read — / 2 Access not recorded — left out of this score
Points 21 / 56 Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 21 of the 56 points we could judge it on is 38 out of 100.
Total 38 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Brain scans and imaging

Also tagged “optical”

151 studies in the library carry the topic tag “optical”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 151 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Brain scans and imaging

See all studies in Brain scans and imaging →